Genitourinary Cancers | Specialty

Novel Combinations Under Study in Advanced RCC

April 12th 2021

The activity and safety of investigational combinations will be subject to study in patients with advanced clear cell renal cell carcinoma (ccRCC) as part of a phase 1b/2 umbrella platform trial.

Dr. Marron on an Adjuvant Personalized Neoantigen Peptide Vaccine for Several Malignancies

April 10th 2021

Thomas Urban Marron, MD, PhD, discusses primary objectives of a study examining the use of an adjuvant personalized neoantigen peptide vaccine in several malignancies.

Research Runs Rampant With Immunotherapy in Urothelial Carcinoma

April 9th 2021

Sequential chemotherapy and immunotherapy became the preferred standard of care in patients with advanced urothelial carcinoma, based on findings from the phase 3 JAVELIN Bladder 100 trial.

Avelumab Maintenance Makes a Mark on the Bladder Cancer Treatment Paradigm

April 9th 2021

Robert Dreicer, MD, discusses the optimal use of checkpoint inhibitors in urothelial carcinoma.

Adjuvant Pembrolizumab Demonstrates Superior DFS Over Placebo in Post-Nephrectomy RCC

April 8th 2021

Single-agent pembrolizumab resulted in a significant improvement in disease-free survival when used as an adjuvant treatment in patients with renal cell carcinoma following nephrectomy or nephrectomy and resection of metastatic lesions, meeting the primary end point of the phase 3 KEYNOTE-564 trial.

Favorable-Risk mRCC: Combination Regimens Vs Single-Agent Therapy

April 7th 2021

Factors that oncologists need to consider when deciding whether to initiate single-agent therapy or a novel combination regimen as frontline treatment for patients with favorable-risk metastatic renal cell carcinoma.

Favorable-Risk mRCC: Sequencing Therapy

April 7th 2021

Best approaches to sequencing therapy for patients with favorable-risk metastatic renal cell carcinoma following first-line therapy with novel combinations such as ipilimumab and nivolumab.

Dr. Hammers on the Efficacy of Lenvatinib/Pembrolizumab in Advanced RCC

April 5th 2021

Hans Hammers, MD, PhD, discusses the efficacy of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

Choueiri and Motzer Chat on CheckMate-9ER and Other RCC Research

April 5th 2021

In our exclusive interview, Dr. Choueiri and Dr. Motzer discuss the clinical implications of the phase 3 CheckMate-9ER trial in advanced renal cell carcinoma and how to best use the combination in practice.

CheckMate-9ER Sets the Bar for Research With Triplets, Response-Guided Therapy in mRCC

April 2nd 2021

Data from the phase 3 CheckMate-9ER trial has not only confirmed the advantage of cabozantinib plus nivolumab in terms of progression-free survival, overall survival, and responses vs sunitinib in the frontline treatment of patients with advanced renal cell carcinoma, but it has served as additional incentive to push the needle even further with research aimed at evaluating triplet regimens in the frontline setting and response-guided sequencing strategies.